Characterization of pritumumab in murine models and primate safety study Journal Article

   


Authors: Mody, A. A.; Mukthavaram, R.; Jiang, P.; Gangangari, K.; Pillarsetty, N.; Kesari, P. R.; Padul, V.; Kesari, S. L.; Rahbarlayegh, E.; Glassy, M. C.; Kesari, S.
Article Title: Characterization of pritumumab in murine models and primate safety study
Abstract: Pritumumab is a human IgG1 kappa antibody that targets ecto-domain vimentin (EDV) which is overexpressed in several malignant tumors including glioblastomas. To understand preclinical biological activity and safety of pritumumab derived from Chinese hamster ovary (CHO) cells, we evaluated tumor targeting ability, brain-tumor barrier permeability, growth inhibition, and primate safety studies. In-vivo and ex-vivo imaging studies demonstrate pritumumab to cross the blood brain/blood tumor barrier and an 89Zr-labeled pritumumab immunoconjugate showed the antibody specifically targeted tumor cells. In mouse xenograft models, pritumumab inhibited the growth of U251 glioblastoma and PANC-1 pancreatic cancer cells. A 29-day intravenous toxicology study in cynomolgus monkeys was carried out to analyze the safety and toxicity of pritumumab, and no toxic effects were observed. Overall, these data together suggest pritumumab is biologically active and animal models can be used to further understand the various functions of the antibody. Clinical trials in brain cancer patients assessing safety and efficacy of pritumumab as a therapeutic for brain cancer are in process. © The Author(s) 2025.
Keywords: immunotherapy; blood brain barrier; animal models; vimentin; pritumumab
Journal Title: Scientific Reports
Volume: 15
ISSN: 2045-2322
Publisher: Nature Publishing Group  
Date Published: 2025-03-25
Start Page: 10178
Language: English
DOI: 10.1038/s41598-025-95360-9
PROVIDER: scopus
PMCID: PMC11933471
PUBMED: 40128557
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-105000684328&doi=10.1038%2fs41598-025-95360-9&partnerID=40&md5=7e554e94a434f669401a59c9e7e8a921
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Nagavarakishore Pillarsetty
    132 Pillarsetty
  2. Kishore Kumar Gangangari
    11 Gangangari
Related MSK Work